ADVERTISEMENT
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from NewMediaWire
Press release content from NewMediaWire. The AP news staff was not involved in its creation.

SmallCapsDaily: Pasithea Therapeutics Emerges as a Major Player in the Biotech Industry

October 4, 2021 GMT

NEW YORK, NY - ( NewMediaWire ) - October 04, 2021 - Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, was the focus of a featured article recently in leading financial news website and publisher, SmallCapsDaily. The coverage is a comprehensive overview of Pasithea Therapeutics’ progression as a development stage company within the biotechnology industry, with a focus on mental health disorders. SmallCapsDaily explores the unique and attractive aspects of Pasithea Therapeutics, such as its parallel revenue stream and profitable business line, which is generating sufficient cash flows to finance the Company’s drug research. The  SmallCapsDaily coverage illustrates that Pasithea Therapeutics’ positioning and its focus on the research and development of treatments catering to psychiatric and neurological disorders, has primed the Company to emerge as a major player in the biotechnology market. 

ADVERTISEMENT

For  more  detailed information, please visit: https://smallcapsdaily.com/pasithea-therapeutics-an-emerging-biotech-player-with-an-immediate-revenue-generation-upside/

Key Takeaways

  • Pasithea Therapeutics’ operations are focused on developing drugs that target the pathophysiology underlying psychiatric and neurological disorders and it is developing novel pharmacological agents that have an increased level of effectiveness on patients suffering from illnesses such as depression, PTSD (post-traumatic stress disorder), schizophrenia, and others.

  • Pasithea Therapeutics is currently building its drug development pipeline and will be going through the standard IND (Investigational New Drug) application process; it should take a couple of years to commercialize the Company’s first set of therapies.

  • Pasithea Therapeutics has a simultaneous revenue stream launching soon, in the form of intravenous ketamine infusions and related business support services to registered mental health clinics. The company has already established partnerships in locations across Los Angeles, New York City and London.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Its biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders rather than symptomatic treatments, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability.

ADVERTISEMENT

The Company’s secondary operations focus on providing business support services to anti-depression clinics in the United Kingdom and in the United States. The Company’s operations in the United Kingdom will involve providing business support services to registered healthcare providers who will assess patients, and if appropriate, administer intravenous infusions of ketamine, and the Company’s operations in the United States will involve providing business support services to entities that furnish similar services to patients who personally pay for those services. Pasithea has partnered with two successful clinics for immediate exposure in locations across Los Angeles, New York City and London.

Forward-looking Statements

SmallCapsDaily profiles are not a solicitation or recommendation to buy, sell or hold securities. SmallCapsDaily is a paid advertiser and is not offering securities for sale. Neither SmallCapsDaily nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by SmallCapsDaily its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. Small Caps Daily does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers. Information presented by Small Caps Daily may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.

Contact:

SmallCapsDaily


info@smallcapsdaily.com

 

View the original release on www.newmediawire.com